nct_id,brief_title,page_rank_score_brief_title,page_rank_score_brief_title_summary_combined
NCT01752257,EF5 in Melanoma Patients,0.002202055997441502,0.0009999329237003677
NCT01760499,"Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study",0.0007225448326698603,0.0009640457623607384
NCT01748747,Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery,0.0010455950399756604,0.0013185058586374706
NCT01748448,Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome,0.0010234217879049124,0.0007263305480107668
NCT01703507,Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma,0.0008950802980249832,0.0009580159553185765
NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,0.00220205599744151,0.002411716500379294
NCT01777802,"Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy",0.0009619471873861171,0.0007623713344373913
NCT01727076,"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer",0.0010540249665313567,0.0012316108589235447
NCT01723813,Peptide Vaccinations Plus GM-CT-01 in Melanoma,0.0010586668332141554,0.0011186218647058924
NCT01744171,Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma,0.0012901637744825072,0.0014583900508639567
NCT01744860,Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples,0.0007697852054493765,0.0009547795053133943
NCT01767454,Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,0.0009501846876492116,0.0009640634237606396
NCT01704287,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002),0.00102215489079675,0.0008820616065373357
NCT01776905,In Vivo Real-time Detection of Circulating Melanoma Cells,0.0010557969146349749,0.0007514068651276536
NCT01740401,CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma,0.00109029374163627,0.001073790702362173
NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,0.0011229294343264925,0.0010033674150472377
NCT01729663,"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients",0.0011561600651983333,0.0011377558874025395
NCT01701037,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,0.0011299753714438718,0.0012973636180877675
NCT01701674,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,0.0009132336690756307,0.000979849929809913
NCT01789827,Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy,0.00115197292845355,0.0011711639816231055
NCT01721746,A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037),0.001214108352003206,0.0012092669318900246
NCT01721603,A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,0.0008681628543819018,0.0009136179753586202
NCT01708941,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.001124868733719886,0.0012227703381274585
NCT01753089,Dendritic Cell Activating Scaffold in Melanoma,0.001489134759624567,0.0008984768761786631
NCT01754376,Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma,0.0010471944104121801,0.001047383878882313
NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,0.0009226391150385435,0.0010410552196034103
NCT01775514,"A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics",0.0008541286040596198,0.0008770062366656354
NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,0.0008809354004177922,0.0009940943548839205
NCT01781026,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,0.001125647952694142,0.0009254630864717513
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,0.001430793390624341,0.0011637091736439468
NCT01709162,Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma,0.0009808227595075629,0.0011869773434438774
NCT01782508,A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma,0.0008980554070717413,0.0008927470725573363
NCT02836548,HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma,0.0008430448476919802,0.0010515371965340895
NCT02891616,18F-FLT PET Imaging in Patients With Advanced Melanoma,0.0011752138533446367,0.0011722034232789478
NCT02879474,Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma,0.0010181499418794437,0.0008369798338305013
NCT02819843,"A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",0.0008748960026191511,0.000901145569287562
NCT02884362,Prospective Melanoma Database,0.0014491462581061002,0.0005277858889169122
NCT02883933,Clinical and Histological Features of Head and Neck Melanoma,0.0010372027926773024,0.0005801712768135542
NCT02828202,Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients,0.0012954004363712357,0.0014499148215955284
NCT02828345,Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma,0.001228579407621757,0.0012092682128676286
NCT02874040,Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser),0.000735701666580176,0.0009359832876724816
NCT02858869,Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,0.0007765422537253422,0.0009652903386409342
NCT02858921,"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma",0.0008261328145327477,0.0010305268742224541
NCT02854124,Tracing Dissemination of Melanoma Cells in Healthy Tissues,0.0010625730641275226,0.0008830869028315586
NCT02854657,Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners,0.0010674254623316234,0.0009399183915083138
NCT02897765,"A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",0.0010087687681564392,0.0011660788766210647
NCT02818023,Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,0.001032306759360274,0.0013097073601423719
NCT02838433,Study of Anti-telomerase T CD4 Immunity in Melanoma,0.0012549859713842436,0.0010225485492412953
NCT02870244,Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes,0.0008828898692785131,0.0007594810294574087
NCT02862145,"Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions",0.0011325047106941408,0.0009714930083777165
NCT02862743,Molecular Characterization of Advanced Stage Melanoma by Blood Sampling,0.0008201303585485686,0.0008389586187754467
NCT02823405,X4P-001 and Pembrolizumab in Patients With Advanced Melanoma,0.0013621271227134573,0.001097218672315485
NCT02857374,Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy,0.0010034897212973834,0.0010943571893854372
NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,0.001527167094205977,0.0012819783692697721
NCT01588847,Anesthesia and Cancer Recurrence im Malignant Melanoma,0.0008474717233059392,0.0007546429105626241
NCT01557114,Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma,0.0014133996985579377,0.0014377248571889917
NCT01528774,Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers,0.0007562247432981347,0.000881599517831963
NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,0.001213809376211222,0.0010702128086694303
NCT01519427,Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib,0.0011191026859284933,0.0013397220654790638
NCT01586403,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients,0.0012232264332750664,0.001066695139591658
NCT01551693,STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma,0.0012954004363712357,0.0010297966225917027
NCT01522664,A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma,0.001288609191687146,0.0010169750135716408
NCT01590082,"Doxycycline, Temozolomide and Ipilimumab in Melanoma",0.000913756650124266,0.0009895038613719658
NCT01585415,Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,0.0008638941613329546,0.0011655978867632203
NCT01585350,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,0.0010755955343185264,0.0010478415233601802
NCT01502293,Trial of pIL-12 Electroporation Malignant Melanoma,0.0010292963106361959,0.0010410883885751002
NCT01502696,Adjuvant PEG Intron in Ulcerated Melanoma,0.0010224298811793075,0.0010531242077652546
NCT01558349,Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques,0.0014521156062505772,0.0010904677863946776
NCT01546571,"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients",0.0012377391579652041,0.001512571116860591
NCT01531608,Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma,0.0008524672686712182,0.0008632478819853754
NCT01531244,"Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma",0.000816324267008975,0.001154853011764483
NCT01565837,Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,0.0008429178995826026,0.0010610653055494006
NCT01500304,Minimally Invasive Groin Dissection for Melanoma,0.0008296042978981924,0.0008920841439385369
NCT01563614,"A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain",0.001007010362082287,0.0008263367279897013
NCT01530698,Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients,0.0012385829980325193,0.0010907313565592966
NCT01533948,Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery,0.001085703067266506,0.0013910397988401255
NCT01584648,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,0.0009180973504025518,0.0009445567467728926
NCT01556503,Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis,0.00084428782865029,0.0008720169997370263
NCT01503827,Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma,0.0007712637440530447,0.0007227759823085845
NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,0.0012156830826441135,0.000793169844440973
NCT01543113,"cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project",0.0007805180394689591,0.001080360516464981
NCT02203604,High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,0.0011234900135357931,0.001356452491710017
NCT02203864,Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma,0.0011773429135800565,0.0012109050561447882
NCT02223884,A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy,0.0009014971376275165,0.0009680021927417754
NCT02257424,"The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",0.0010580684583089272,0.0011554286119126193
NCT02251314,Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma,0.001068566605457304,0.0008414326381529072
NCT02259231,RTA 408 Capsules in Patients With Melanoma - REVEAL,0.0012143290614388118,0.0014390893730864376
NCT02225366,Intratumoral Injections of LL37 for Melanoma,0.0014592843099860643,0.0010931808837276115
NCT02275416,Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma,0.0010998269537524621,0.0011429606156234933
NCT02285413,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,0.0012142859109213556,0.0009946884803974261
NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,0.000868889773240279,0.0009827248190878558
NCT02211131,Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma,0.0009021626761818069,0.0010533140261730649
NCT02297529,Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma,0.000979665392810558,0.0011483356609412892
NCT02236546,FDG-PET in Advanced Melanoma,0.0011893768772241085,0.0010643106630321313
NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,0.0013557838392271747,0.001295744785589179
NCT02263508,Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034),0.0008716428232539622,0.0008117444057473072
NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,0.0015780429359842564,0.001137416281487761
NCT02200562,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,0.0008704004863931855,0.0011146885715992007
NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,0.0011089466792327499,0.0012501612761383633
NCT02231775,Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo),0.0010493140401630844,0.0011007641236992654
NCT00590824,Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma,0.0010674157529197415,0.0008229143595688636
NCT00591500,A Model for Genetic Susceptibility: Melanoma,0.0008311555880574157,0.0007267647274773057
NCT00591370,Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma,0.0012349305983087664,0.0010797053478963608
NCT00518206,Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma,0.0013002257874685692,0.0011680148896350794
NCT00518895,Trial of Dacarbazine With or Without Genasense in Advanced Melanoma,0.0009716710664997037,0.0009117457431453809
NCT00580320,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,0.0009029904151352701,0.0009241420874836583
NCT00580060,"Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity",0.0009877612022453387,0.0011333471837369634
NCT00539591,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,0.0009656642374499397,0.0011272910801307893
NCT00577382,SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma,0.0012625763780554633,0.0009574658517581969
NCT00510302,Melanoma Risk-Reduction Among Patients and Family Members,0.0012138036077208299,0.0007044894361585294
NCT00584493,Treatment Use Study for Advanced Melanoma.,0.0011961959088296536,0.0014653850596454134
NCT00581698,Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue,0.000696285995666435,0.0008397071117285434
NCT00526032,Melanoma Detection by Oblique-Incidence Optical Spectroscopy,0.0010273993714684584,0.0005996895162177334
NCT00565968,Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg,0.0010261156359263463,0.0010133866262694922
NCT00596362,Treatment With Intravitreal Avastin for Large Uveal Melanomas,0.001108893945103297,0.0011036404937836161
NCT00533702,A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma,0.0010727469814963667,0.0010644223506413985
NCT00553618,"Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients",0.0010126764899616582,0.0011283845312210048
NCT00553306,Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma,0.0010675035464225888,0.001133126225124536
NCT00559026,Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients,0.0011685528628949688,0.0010352400168838138
NCT00525031,Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients,0.0010162899782020713,0.0013794225385577602
NCT00522834,Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma,0.0008468526745235006,0.0007635888517554648
NCT00521001,Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,0.0011123974856938543,0.0011002720152844116
NCT00585000,"A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma",0.0012183740668069245,0.0012993664407487142
NCT00515983,Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells,0.0010902416228443605,0.0012131165313588302
NCT00588198,"Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma",0.0009665148813096498,0.0012368494461544063
NCT00588341,Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection,0.0010617326904106077,0.0011952071284208404
NCT00535314,Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma,0.0012203617005637731,0.001296299484780696
NCT00506311,Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients,0.001222638714375106,0.0006911615296216006
NCT00543205,"Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment",0.0007585566337080774,0.0006806258285986784
NCT00568763,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,0.0010274394640353264,0.0010011944505122425
NCT00568451,Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma,0.0011053291913649132,0.001094482226658518
NCT00568048,Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011176686503510667,0.0010824357252732864
NCT00507325,Sample Collection From Melanoma Patients,0.0015262053186412788,0.001195784107401429
NCT00536029,MicroRNA Expression and Function in Cutaneous Malignant Melanoma,0.0010265420266530492,0.0006700625066661215
NCT00512798,Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma,0.0011249593597276622,0.0010486712781895436
NCT00512889,Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma,0.0014505958179251287,0.0009075889561448766
NCT00527761,Taxotere/Temodar/Cisplatin Study in Melanoma Patients,0.0011257025309866517,0.0011022343178443675
NCT00527657,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.001081030377155767,0.0010499228915145677
NCT00504582,Fibrin Melanoma Axillary Node Study in Patients With Melanoma,0.001208936849093675,0.000888367264229225
NCT00538005,"Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",0.001033084501628762,0.0010301399184951888
NCT02739386,Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases,0.001154307404881717,0.0009754262887126249
NCT02731729,Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,0.0011176135402378297,0.001102641462799403
NCT02791594,Imaging FDG Flare in Melanoma,0.0010328325891621627,0.001001132634922198
NCT02723721,Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face,0.0008314518095780488,0.0008357924032568003
NCT02723006,"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",0.0009253418533527063,0.001045179523551527
NCT02717364,"Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma",0.0011009065939386966,0.0009442256790347407
NCT02799901,Nivolumab Plus Radiotherapy in Advanced Melanoma,0.000993564349345831,0.0008238363010750512
NCT02794636,Interferon Toxicities in Melanoma Treatment,0.000903414146536798,0.001049060947642265
NCT02716948,SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,0.0009865444306492745,0.0012062488946852157
NCT02716077,Early FDG PET in Melanoma,0.0014491462581061002,0.0007924178661255089
NCT02748564,Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.0011765094520740898,0.0013303380280315633
NCT02744209,Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients,0.001120095996303035,0.0012555926567047657
NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,0.0008929946865447845,0.0011616312805527234
NCT02718391,Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.,0.0010679652670562334,0.0009686593511107068
NCT02718066,"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",0.0009083398803692647,0.0013402968721680497
NCT02768207,A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma,0.0009034814561252657,0.0009029236298499557
NCT02796352,A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,0.0012563993194396462,0.0011924980318855662
NCT02759536,In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma,0.0011107961816707783,0.000910138715909313
NCT02700763,[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis,0.0010450043246256048,0.0009672164752648839
NCT02738489,A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Melanoma Subjects,0.0010089880641554988,0.0011978490867328073
NCT03028948,Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma,0.0009817625236639062,0.00094967163833649
NCT03084640,Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,0.0009796146252896247,0.0009102254055473627
NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,0.0008687935317742395,0.0009407822306384374
NCT03089606,Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,0.0007335165072537814,0.0007947427058996506
NCT03064763,Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma,0.0009693891419801164,0.001402207713368948
NCT03034395,Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma,0.0011270360950192254,0.0012552591837586974
NCT03026517,Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,0.0010085508583319318,0.0010050653807793328
NCT03007823,High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma,0.0007819950959279447,0.0011964530554581794
NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,0.0011874251110233671,0.0010443082674418032
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",0.0010455300559415607,0.0010977236342589716
NCT03021460,Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011019255944356653,0.0013092256580977102
NCT03068455,An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab or Ipilimumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma,0.0009959049369216131,0.0010395543038264517
NCT03003676,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",0.00121462134242814,0.0010103317198702322
NCT03086174,Tolerability and Pharmacokinetics of JS001 in Combination With Axitinib in Patients With Kidney Cancer and Melanoma,0.0010265385616736427,0.001209376366990685
NCT03057327,Promoting Early Detection of Melanoma During the Mammography Experience,0.0008296497132070903,0.0006251632603330909
NCT03012009,Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial,0.0007254216641505465,0.0006884963231441132
NCT03073031,The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy,0.001548063200096874,0.0009330325979325037
NCT03069846,"Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope",0.0008348011743518729,0.0004973609507373673
NCT03002376,An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1),0.0010917979064218467,0.0011641756085993096
NCT03024866,Electronic Brachytherapy (eBx)-Mohs Matched Pair - Cohort Study A Multi-Center Retrospective-Prospective Matched Pairs Cohort Study to Assess Long-term Clinical Outcomes of Non-melanoma Skin Cancer Patients Treated With eBx Compared to Non-melanoma Skin Cancer Patients Treated With Mohs Surgery,0.0010713237748894227,0.0009309073090000378
NCT03033576,Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,0.0012069265564921407,0.0013800772871483298
NCT03033485,18F‐Labeled Picolinamide PET Imaging of Melanoma Diagnosis,0.0007521003425653328,0.001002151001698579
NCT00203008,A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma,0.0011271017280523573,0.001179642878470121
NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,0.0007859604418357806,0.0008372456750479183
NCT00255762,"Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",0.001093422125777519,0.0010753204464376241
NCT00243529,Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients,0.0010263030434959936,0.0011595785455861055
NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,0.0010142264607050386,0.0009530843042886031
NCT00243061,AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma,0.0016937643708056847,0.0013450417205026711
NCT00204607,Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients,0.0010318959497781712,0.0010508854604149563
NCT00204529,Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB,0.0012556836766076257,0.00120362696601601
NCT00204581,Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases,0.0007683632354852332,0.0009323360891370238
NCT00235482,Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma,0.0010292544084321512,0.0012919405872024352
NCT00278122,Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011780863776732883,0.0012850736242950524
NCT00264056,Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases,0.0010689782027247538,0.0011697364096515924
NCT00281957,Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery,0.0010786585123036838,0.0010370442736366795
NCT00281541,A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma,0.0010822288458660078,0.0014450906507551685
NCT00288938,Natural History Study of Moles and Suspicious Melanoma,0.0008860882908046431,0.0009104790543714374
NCT00294476,"IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma",0.0007932182478643614,0.0012529569329280655
NCT00246012,"A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma",0.0009393688926296231,0.001140488278640049
NCT00273910,Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma,0.0007801394189384922,0.00140575710593704
NCT00217542,Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery,0.0011538929366361978,0.0011512224538348394
NCT00232726,Clinical Study of Previously Untreated Patients With Malignant Melanoma,0.001222563342292517,0.0011644574981308532
NCT00200577,Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma,0.000778263897509607,0.0009606540395455838
NCT00289640,Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012848730261552249,0.0014717928167194774
NCT00289016,A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma,0.0011674234406136282,0.0013466961500346749
NCT00289627,A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0012203451066339578,0.0012156284940249584
NCT00226473,Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma,0.0007474800209174477,0.0010137000640719764
NCT00258687,"Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma",0.000801301701355586,0.0010243311675139281
NCT00257465,"Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma",0.00117305496643634,0.001242221360494117
NCT00272415,"A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma",0.0011151686556768758,0.001021977632068795
NCT00287196,Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes,0.000749500426821131,0.0006665851364754467
NCT02366195,Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma,0.0007080136334300565,0.000987301964267969
NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,0.0008589751479438838,0.0008728130502869334
NCT02352623,Quality of Life and Surgical Late Effects of Melanoma Treatment,0.0009513398509850942,0.0011047592851428
NCT02335476,Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography,0.0008347963165459116,0.0006668399605318457
NCT02332668,"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",0.0009227680358023274,0.0009913376299807355
NCT02310451,Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes,0.0008897509743269552,0.0010988312984502072
NCT02306512,Mohs and Immunofluorescence for Malignant Melanoma In Situ,0.0014491462581061002,0.0009639093877650952
NCT02306850,Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,0.000929621856751115,0.0011501123224124821
NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),0.0009160811882086823,0.0008926673318855124
NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,0.0012239571675683905,0.0011609595262566184
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",0.0008316149015927222,0.0008360986526704249
NCT02375984,A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas,0.0008771268624386717,0.0010094075544838596
NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),0.0009583373574633319,0.0010297517147659766
NCT02385669,A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,0.0011287557431310159,0.0012327827986266873
NCT02385214,MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma,0.0010243605164430914,0.0006878566935393233
NCT02385253,Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance,0.0006962310059190722,0.00047682309321795183
NCT02374242,Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases,0.0012389805164447778,0.0012681191657073609
NCT02320058,A Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab by Itself,0.00115887133451821,0.0011140967156039064
NCT02320305,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,0.0010135723379586592,0.0011662741281610299
NCT02372708,Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy,0.0008633735490352916,0.0007087123161497609
NCT02327390,Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma,0.001099636166513648,0.0013075622281990076
NCT02318771,"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer",0.0010023967228883473,0.001157155461223404
NCT02302339,A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma,0.0012036991114073685,0.0012610275863101494
NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC,0.0008687935317742395,0.0009309750009751114
NCT02331134,Tissue and Hematopoietic Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer,0.0006967303822382854,0.0008350003546514566
NCT02355574,5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results,0.0007993762174448642,0.0006517490235784802
NCT02355587,Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes,0.001127259795542148,0.0008493345405729531
NCT02307149,Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,0.0013663586088378853,0.001490745559881936
NCT02301611,Phase IIB TL + YCWP + DC in Melanoma,0.002777704469023434,0.0009193364081512349
NCT02316795,Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma,0.0008384639671151608,0.0007975284142993383
NCT02393001,Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques,0.0007003024475498895,0.000801205230103241
NCT02339571,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.001127054454556594,0.0012579903443859725
NCT02339987,Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration,0.0008668950425744949,0.001244001831544951
NCT01308294,Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients,0.0010903825375178722,0.0012103583361638848
NCT01308762,"A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients",0.0011142017692475517,0.0013673755679319182
NCT01388569,Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim,0.0011000865261705053,0.0011850615674599023
NCT01336270,"Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients",0.0010893116035342247,0.0010691403352102657
NCT01341158,NAM-Trial: Multiferon in Malignant Melanoma,0.0014491462581061002,0.0008313653898459783
NCT01328535,Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.001158342597498982,0.0013042910488577503
NCT01303341,Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,0.001108851138436426,0.0012837253863074202
NCT01320085,A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma,0.0012252788689176806,0.0012218406859241357
NCT01321437,Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,0.001162852653316336,0.0014045915918628792
NCT01311466,Liver Transplantation and Uveal Malignant Melanoma,0.0014491462581061002,0.0010305380072077644
NCT01323517,Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,0.0008790581421761259,0.0010377816926879317
NCT01356771,Melanoma Risk Assessment & Tailored Intervention,0.0010224060584541647,0.0006681162254662353
NCT01302496,Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0011674585516997299,0.0010373097147031102
NCT01355120,THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease,0.0013395503382020342,0.0011041630548925731
NCT01355562,Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer,0.0007453593399014766,0.0009600814657340378
NCT01359956,Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma,0.0008563954703441312,0.0010295990375963516
NCT01397708,Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma,0.0009240002138364581,0.001033333054768379
NCT01338389,Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy,0.000997709844184036,0.001034900250045828
NCT01316692,Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma,0.00118994238602803,0.0011442859795987223
NCT01368276,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,0.0012539947112275838,0.0012915835542732074
NCT01363206,Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma,0.0008007902562810046,0.0009415027931469508
NCT01313429,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum",0.00103252243114763,0.0013595319854070227
NCT00815607,Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma,0.0011775945579608567,0.0011713492867160495
NCT00813449,Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma,0.001188358320128875,0.0010333537417016017
NCT00871533,Pilot Study of IFN α2b for Melanoma Patients,0.001755885322770282,0.0010848890604834784
NCT00811759,Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma,0.0011812968157870476,0.0011568093455209551
NCT00816374,Tailored Intervention for Melanoma Patient's Families,0.0015252312462993877,0.0008266800215217366
NCT00831545,"Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)",0.0008522513534660667,0.000977774816990354
NCT00866177,MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma,0.0012546254498485914,0.0012807836869180784
NCT00866840,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011726180388929159,0.0013087843497081749
NCT00862914,"Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi",0.0006930043398049783,0.0006343251533425986
NCT00862901,Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma,0.0010740639905809125,0.0010456212767914678
NCT00835419,Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression,0.0008965604602687045,0.0013970033137039577
NCT00835133,"Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma",0.0009583775396292721,0.0009486609059095644
NCT00861406,Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine,0.0008354090466285946,0.000875874031814004
NCT00849407,Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma,0.0007370616535479095,0.0007178728024307092
NCT00889980,Melanoma Molecular Profiling Analysis,0.0014536253869651475,0.0007596708873278149
NCT00847106,Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients,0.0010704369586776812,0.0013245989640956997
NCT00847522,Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma,0.0010135691429101932,0.001013962404137732
NCT00897520,Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy,0.0010866971072299014,0.001169966999826164
NCT00897481,Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy,0.0010992840366833222,0.0011113000523473983
NCT00897546,Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma,0.001079610107545902,0.001144842779972491
NCT00826995,Comparison of Video-Based Versus Written Patient Education on Melanoma,0.0010631501138203285,0.0010808165434759583
NCT00809588,"Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)",0.0006999665323183912,0.0009114565949726232
NCT00841204,Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma,0.0010224340615893654,0.0008201448351737742
NCT00839410,Multicentric Cohort of Melanoma Patients in Ile de France Area,0.0015242502985216868,0.0009015806025733519
NCT00803374,Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma,0.0013165997611953655,0.0016674317038365117
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,0.0011177867066905188,0.0011732805423070153
NCT00846833,Haploidentical NK Cell Infusion in Malignant Melanoma,0.000855596469121476,0.0009517035149344018
NCT01644591,Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases,0.0010014486501396652,0.0010501414547947807
NCT01673854,Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma,0.001063167404102968,0.00149890275995509
NCT01657591,Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,0.0012572247891799496,0.0009659402146748055
NCT01676649,Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma,0.0011798901228143794,0.0010751785388065384
NCT01676779,mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma,0.0009706708441315095,0.0010159024980106982
NCT01621490,PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma,0.0009938962243770638,0.0012467332860612202
NCT01636882,Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks,0.0015689565140426355,0.0012947859046323795
NCT01636960,A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370),0.0012707172938316142,0.001144534004817202
NCT01666418,Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel,0.0011638280942338542,0.0013202948500409208
NCT01610531,COPARIME: Pilot Study of a Target Detection of Malignant Melanoma,0.0012589934512337265,0.0008440936354064926
NCT01622933,Multiple Antigen-Engineered DC Vaccine for Melanoma,0.0014857041355090539,0.0006614033476330993
NCT01681212,Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma,0.0012784605639746872,0.0013455757269495159
NCT01614301,"Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma",0.0010903669560578127,0.0011641950733801705
NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,0.0010706739813936526,0.001465628680644133
NCT01682083,A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,0.0009383434422337887,0.0010275028533062811
NCT01672450,A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma,0.0011774558144798614,0.0010231619360435433
NCT01677975,"The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma",0.000956684427675507,0.0010965746011307106
NCT01611675,Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma,0.0014491462581061002,0.001211450855754685
NCT01662713,Optical Frequency Domain Imaging for Non-melanoma Skin Cancers,0.0008429169312150834,0.0007975310407124878
NCT01608594,Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma,0.0009038474605639781,0.0011162893678486972
NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,0.0012382634532188555,0.0011641236460877573
NCT01667419,BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,0.0011537724357179218,0.0008894569628707241
NCT01605162,Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma,0.0010194684230842937,0.001108856342062077
NCT01696045,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",0.0009833233448465148,0.0010234876566945462
NCT01616199,Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma,0.0013337322211589427,0.0011546073400772968
NCT01037127,Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor,0.0009003868048570737,0.0009376736115461299
NCT01052142,Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma,0.0012778724080545604,0.0011408731588681076
NCT01082198,Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes,0.0010901482106785458,0.0011063184616879806
NCT01078961,An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,0.0009634671019789293,0.0010189293586915008
NCT01039844,Study of Weekly LOC-paclitaxel Injection for Melanoma,0.0010128188566703355,0.0010519552038983511
NCT01003626,Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients,0.0012082189775871324,0.0012390344050200882
NCT01026051,"Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma",0.001023007869694472,0.0010352253034484052
NCT01026324,Dinaciclib in Treating Patients With Stage III-IV Melanoma,0.0013246648008584112,0.00123196710844131
NCT01067066,A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma,0.0010684880141731607,0.0010564921376088276
NCT01085396,Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin,0.000679219130457767,0.0007063134688976923
NCT01034696,Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting,0.0009803952207940916,0.0010647189728252293
NCT01028222,A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,0.000981054644955052,0.0014249483744998728
NCT01010984,LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma,0.0007464213316033081,0.0011076576680699504
NCT01021059,A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer,0.0008726786234929842,0.0014647724334646973
NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.0010715677570289908,0.0011212384900552137
NCT01002560,The Identification of Novel Prognostic Markers in Melanoma,0.0008455104576009511,0.0010162882497313733
NCT01077050,SciBase International Melanoma Pivotal Study,0.0017944866535682719,0.000784061311249855
NCT01005472,Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.0011752090722181637,0.0011256678524741851
NCT01092585,Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH,0.0010922182957907999,0.0010758725463501984
NCT01092728,"Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",0.0010013875509312167,0.0011901063291157726
NCT01011530,Dose Escalation Study of MLN4924 in Adults With Melanoma,0.0017944866535682719,0.001162787581803072
NCT01009775,A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma,0.0010426917529060757,0.0012032421331692378
NCT01079741,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,0.0014096932219285303,0.0011090417176203918
NCT01066390,A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma,0.0011758194110810896,0.001248888775418559
NCT02425475,FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA),0.0010273913278815788,0.0004973231222744506
NCT02425306,Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,0.0009777686251974324,0.0010272231367727217
NCT02400385,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,0.0009762468406793076,0.0010229867656943177
NCT02442466,Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma,0.0008896377871237825,0.0008162948571850473
NCT02457065,Skin Care Behaviors Among Melanoma Survivors and Their Families,0.0010224463012528746,0.000745962285291775
NCT02410733,Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma,0.0010666399546273712,0.0013602356771626372
NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,0.0008446958828041893,0.0010809342402018712
NCT02437279,Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients,0.0011686323757303973,0.0013153589098163956
NCT02437305,Melanoma Perception and Health Literacy in People of Color,0.0008280903420839399,0.0006759488260918263
NCT02437136,Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,0.0009081553240468161,0.0009574757924828177
NCT02492815,"PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma",0.0011286185954261926,0.0012669234527899983
NCT02452424,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,0.0009670280928882957,0.0011959175242889537
NCT02452294,Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER),0.0010730026673805096,0.0010380620073963277
NCT02452281,Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,0.0012459619625664257,0.0013936639252262785
NCT02470273,Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID),0.0009994351840946585,0.0007793862278234079
NCT02402699,Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan,0.0010884023337558266,0.0007743164799243996
NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,0.001189493558938727,0.0009066354234731641
NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,0.000954446203621292,0.0009795737021075655
NCT02434107,"Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)",0.0009659779448980883,0.000831355777012943
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,0.0012341821705562645,0.0012085767561838504
NCT02403778,Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma,0.0009119695577736886,0.0013334998242016552
NCT02460068,A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis,0.000971951670688232,0.001029784285325234
NCT02451488,Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma,0.0007369542179523181,0.0007063238648674762
NCT02447939,Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma,0.0008028576183734622,0.0009404054163312075
NCT02424916,Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study,0.0011048386788546968,0.0010557085431291407
NCT00101166,Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma,0.0006937342561218053,0.0009058941761019583
NCT00104845,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.001217411230587593,0.0012726855526269262
NCT00104884,FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0012954004363712357,0.00125901134696573
NCT00104988,S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011143849235727898,0.0011320805747361024
NCT00104897,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma,0.0012611027405974974,0.0011356238486103193
NCT00121225,Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma,0.0011393220376023317,0.0012015594634331302
NCT00184067,Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma,0.0010114073674779738,0.0010706008021708424
NCT00179608,Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy,0.0011346834731939736,0.0010441097984734786
NCT00110019,Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011508268668223498,0.0013329660017511187
NCT00110994,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,0.001028032856131942,0.001065096645652427
NCT00119249,Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011775348163280213,0.0011778698772643673
NCT00142454,NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting),0.0007576437522171509,0.0010347940149069387
NCT00125749,Vaccination of Patients With Stage IV Melanoma With Dendritic Cells,0.0011951178589264247,0.0013493446457990758
NCT00109863,Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma,0.0013411017150511725,0.0013383897059219706
NCT00160992,Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients,0.0009732528552323128,0.0008885226907640573
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,0.0012232915829018109,0.0012412956262131075
NCT00111696,Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma,0.0011842770361255354,0.0014324411251506368
NCT00128583,Vaccine Therapy in Treating Patients With Malignant Melanoma,0.0015787104876690944,0.0012662319689736956
NCT00199901,"Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma",0.0011469180715928521,0.0012403837088679657
NCT00199342,"A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma",0.0012256157133231406,0.0009560032568129903
NCT00118313,"Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.0011685716037513044,0.001287864254775255
NCT00118274,"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",0.00116953265122896,0.0013241427351916388
NCT00147550,"MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",0.0008483403885567452,0.001051874318917529
NCT00112242,Immunotherapy of Stage III/IV Melanoma Patients,0.001343113772594543,0.0010474480919428783
NCT00112216,Immunotherapy of Melanoma Patients,0.001548063200096874,0.001101351527783406
NCT00112229,Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients,0.0011754418362919332,0.0013739521089673936
NCT00153569,Multiepitope Peptide Vaccination in Melanoma,0.0010586668332141554,0.0008379290921173821
NCT00116363,Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma,0.0012099728932458513,0.001590213875887365
NCT00107159,Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma,0.0012024449332157646,0.001237755623220337
NCT00108875,"Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer",0.001053808092896105,0.0012075741526059935
NCT00145041,Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction,0.001086406633727758,0.0010426094603419034
NCT00126685,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013812566106214097,0.0011961460588338759
NCT00197912,Dendritic Cell Based Therapy of Malignant Melanoma,0.0011350408017754363,0.0011232209429510134
NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",0.0011508986197447117,0.001096743111605821
NCT02180061,Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041),0.0011560774855946879,0.0013148094618346592
NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),0.0009679474530005404,0.0009767953078414072
NCT02177110,A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma,0.0008542669753081845,0.001001445886783827
NCT02112032,Treatment of Advanced Melanoma With MK-3475 and Peginterferon,0.001018112398613034,0.0011032923802974368
NCT02166255,"APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery",0.0010496318628785849,0.001186511078743464
NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",0.0009967467885733854,0.0010691389117461262
NCT02147951,"Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma",0.0008761600893979222,0.001346475728327169
NCT02193581,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.0006995676052205524,0.0006966732151274231
NCT02106598,"Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Breast and Gynecologic Malignancies",0.0006822781519588551,0.0009529202694814371
NCT02129075,CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,0.0011207186314578118,0.001254427615957938
NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,0.001036118632752894,0.001320836110926654
NCT02190838,Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma,0.0007178665912120895,0.0008421848009215686
NCT02120222,Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,0.0013050736048534671,0.0012440670342630407
NCT02158520,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011197328244530041,0.001340390298833773
NCT02156804,"A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",0.0008819586244076742,0.0010328917015672552
NCT02196181,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,0.0011075611430548529,0.0012653315959522782
NCT02155322,A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400),0.001079944820677882,0.001760011629694004
NCT02115243,Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,0.0010300959384444057,0.0011470497333735965
NCT02115139,GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases,0.0011504594411697617,0.0011752825512478748
NCT02142218,Expanded Access Program With Nivolumab to Treat Melanoma,0.0010528156308839388,0.0011272465681133688
NCT02142335,Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma,0.001116652043450421,0.0012923417912360587
NCT02142244,Fluorescence Surgery for Sentinel Node Identification in Melanoma,0.0008895621095247616,0.0007351628706310511
NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,0.0009946955732464968,0.0011736914125320883
NCT02141542,Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,0.0011541098972577403,0.0010762123662530184
NCT01174238,A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852),0.0008376202642141999,0.0009468335136614438
NCT01120275,Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma,0.0013397156589239094,0.0011593795371560467
NCT01106040,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,0.0008393379138480989,0.0006014520070045292
NCT01127594,Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion,0.0009859089705879988,0.0012298955790336847
NCT01127451,Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma,0.00124211147963722,0.0013195975790028325
NCT01189383,"IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma",0.0011710266848390545,0.0012984095426053107
NCT01183936,Trial of Surgical Excision Margins in Thick Primary Melanoma,0.0010968572734142042,0.0009696151070932326
NCT01138410,Study of a DNA Immunotherapy to Treat Melanoma,0.001276831656225399,0.001123975264289813
NCT01133977,E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma,0.00107144543717586,0.0008654666090406395
NCT01191294,Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma,0.0007115529884156644,0.0005040703522221663
NCT01121718,NIR-Guided Sentinel Lymph Node Mapping in Melanoma,0.001024522040563307,0.000770244472595581
NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,0.0008776463194138934,0.0011270567512536547
NCT01134614,Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011988133420595304,0.0011467737808879593
NCT01137006,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma",0.0013953527529665505,0.0013084047819305097
NCT01124734,High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma,0.0009916260905652985,0.0009979414564292113
NCT01118832,Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi,0.0007173035974478661,0.0005836693986232439
NCT01168050,Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.,0.0008676593205594657,0.0008864204490676119
NCT01176474,Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,0.0010429050634163041,0.001027304892195433
NCT01136967,"An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",0.001005060970168292,0.001125216221482131
NCT02089685,Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),0.000837008232287915,0.0009535454571699476
NCT02071940,PLX3397 KIT in Acral aNd mucOsal Melanoma,0.002777704469023434,0.0012971217406422602
NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,0.0008909932232411559,0.0009103280265862901
NCT02068196,A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.,0.0013663586088378853,0.0009786949310308863
NCT02054520,Immunotherapy Study for Patients With Stage IV Melanoma,0.0013303329578848943,0.0011968729650666356
NCT02009384,Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox,0.000873533345985349,0.0009682528970261602
NCT02009397,A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,0.0012534522273007801,0.001224388637194486
NCT02062359,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma,0.0012522207184122716,0.0013218178203851653
NCT02094391,"Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma",0.0011238261801784495,0.00092409224362441
NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,0.0012621222029328921,0.001156217201174522
NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,0.0008691379479318427,0.0011348338550076476
NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,0.0008587570268472994,0.000980969968174241
NCT02056522,Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging,0.0006995676052205524,0.0006966732151274231
NCT02074605,Cognitive Effects of Interferon in Patients With Melanoma,0.0015370303906687489,0.0009688311525215448
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,0.0012315400090251265,0.0013377653553674563
NCT02029729,RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER,0.0008673408124030898,0.001023921713557102
NCT02058953,"CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases",0.0010347099948497243,0.0009724981826080547
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,0.001237508945517656,0.0010520869925425994
NCT02088762,Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm),0.0012192607199339402,0.0007301294041996669
NCT02077114,Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma,0.0009125814947317997,0.001053662763681448
NCT02097732,Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,0.00104756089126585,0.0011568310301152648
NCT02032810,Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,0.0008286066883191224,0.0009780602390129308
NCT02020707,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers,0.001087202425590523,0.0012493232146455083
NCT00938223,"Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma",0.001064645129278288,0.0010461368056300616
NCT00928902,"Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma",0.0009905756458039483,0.0010521318469471478
NCT00945269,"Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma",0.0010752487988910499,0.001100787090852717
NCT00942162,A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma,0.0012489268548592659,0.0012274005062416617
NCT00936221,Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients,0.0010100174800850422,0.0009701815336492229
NCT00910650,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,0.001244644861562936,0.0013265282112379431
NCT00966173,International Melanoma Algorithm Training Study - IMATS,0.001010942367759635,0.0007552249559215319
NCT00920907,Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma,0.0008401887540272248,0.0010630347123163017
NCT00972933,Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma,0.0008125761312254852,0.0010503018123738535
NCT00901966,Sun Exposure and Melanoma in Agricultural Workers,0.0014506127259666117,0.0006920117066871585
NCT00963664,Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma,0.0008152957148749438,0.001182734055885031
NCT00963261,Quality of Life and Psychological Well-being in Patients With Malignant Melanoma,0.0012145319440191253,0.0011193768499370318
NCT00923169,Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma),0.0012191427286473578,0.0013702993516919635
NCT00978913,Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma,0.0011359028123974371,0.001324187140175101
NCT00979693,Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma,0.0008403578157019742,0.0007583368322459572
NCT00940004,Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients,0.0010891189412498676,0.001099453433011905
NCT00977145,Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma,0.0010104269596063508,0.0011718763461432834
NCT00974610,"Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12",0.00116248662939574,0.0009376519656913477
NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",0.0010023769119638334,0.0010056564438452053
NCT00912730,A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma,0.0008918370339045954,0.000900898467884713
NCT00912418,"Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma",0.0011469947924761784,0.0010197284999163162
NCT00912574,Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38,0.0009775845510290571,0.0009821656425754069
NCT00961844,Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma,0.0011513627625979234,0.0009433784418581956
NCT00961376,Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC),0.0010132433250502446,0.0012187572856310644
NCT00925314,A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma,0.0009871065169546186,0.0008536600964079723
NCT00962845,Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.0011731322690739499,0.0010695040219219796
NCT00991250,SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma,0.001018112398613034,0.0015407429253055567
NCT00991991,"Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma",0.0011977575139228865,0.0012583203188507087
NCT00911443,"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma",0.001027728158685113,0.0011701434137767809
NCT00937625,T-cell Based Immunotherapy for of Melanoma,0.0014841430000922654,0.001197993282231234
NCT00937781,Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690,0.0011608974403984787,0.001226035953918268
NCT00937937,Dinaciclib in Treating Patients With Stage IV Melanoma,0.001340427802777142,0.001266370172564461
NCT00071981,Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma,0.0010114859389223387,0.0011188813476165527
NCT00028431,Novel Adjuvants for Peptide-Based Melanoma Vaccines,0.0010629314046530956,0.0009295075986522219
NCT00017121,Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.0010306282084355596,0.0012228150281834058
NCT00006035,Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011594758130355233,0.0011909605713559702
NCT00006126,"Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery",0.0010223784084762092,0.0012070361494745936
NCT00006243,Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma,0.0012065461526747257,0.00131316170075651
NCT00006237,S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma,0.001226797654510503,0.001010636233414707
NCT00006022,Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer,0.0010759313031426098,0.001257052539666347
NCT00006113,Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011948246956405087,0.0012670707132011005
NCT00006233,"Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma",0.0010374060016646617,0.001235131953835248
NCT00006249,Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma,0.0012007622482052124,0.0011121344336576273
NCT00084214,STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma,0.001045888972194085,0.0014172271880751183
NCT00084656,Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma,0.0011589488210217013,0.0012148050355429668
NCT00042783,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013812566106214097,0.001500358532873868
NCT00042497,Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma,0.0011870567153479115,0.0011668961053797268
NCT00087386,Tanespimycin in Treating Patients With Stage III-IV Melanoma,0.0013246694244314124,0.0010951754750604988
NCT00087477,A Pilot Study of Pivanex in Patients With Malignant Melanoma,0.001390219542962155,0.0012893958911540514
NCT00087776,Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma,0.0011351191923191061,0.0011119761405720037
NCT00083239,Study of Talabostat in Advanced Melanoma,0.0014160438350893972,0.0016989390782608201
NCT00083252,Study of Talabostat and Cisplatin in Advanced Melanoma,0.001133531761828501,0.001347770762664356
NCT00033228,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013812566106214097,0.0013986085647433027
NCT00060710,CP-461 in the Treatment of Patients With Advanced Melanoma,0.0014022455459484233,0.0015832215763578916
NCT00060125,Tipifarnib in Treating Patients With Metastatic Malignant Melanoma,0.0012611164677959572,0.0012429389737570805
NCT00016263,Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma,0.0010958249572830515,0.0010798803075578417
NCT00010309,"Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma",0.0011980755571503589,0.0014152265779327918
NCT00085397,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012898380975264656,0.0012269592502346912
NCT00085189,Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma,0.0012874114272711712,0.0014239937707350623
NCT00085488,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012898380975264656,0.0012726855526269262
NCT00085579,Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.001138124240943935,0.001081978045033754
NCT00074308,Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers,0.0010668221132858473,0.001252064186846188
NCT00014625,E7070 in Treating Patients With Stage IV Melanoma,0.0013397156589239094,0.0014240876652066292
NCT00014092,Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery,0.001128064387163145,0.0014040711438074152
NCT00049530,PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma,0.0013397156589239094,0.001240319892941522
NCT00025181,Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery,0.0011785820996175376,0.0013964625671319963
NCT00003091,High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma,0.0010193953379651574,0.0011475032218465494
NCT00003266,Methylphenidate in Treating Patients With Melanoma,0.0015242502985216868,0.0009384858523526055
NCT00003646,Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012563821830331174,0.0015079314108677072
NCT00003509,Antineoplaston Therapy in Treating Patients With Stage IV Melanoma,0.0012187468127862122,0.0010825794371515727
NCT00003641,High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma,0.0010911503775010887,0.0010541018337230832
NCT00003911,S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases,0.0007279883331288315,0.0009511252143801754
NCT00003346,Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.001255790646574907,0.0013349046974972505
NCT00003308,"Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma",0.0009918454759440941,0.0011270344895434972
NCT00003647,Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma,0.0011837497204153548,0.001208648590861298
NCT00003556,Vaccine Therapy in Treating Patients With Melanoma,0.0015787104876690944,0.0014211675739799754
NCT00003715,Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma,0.0011907572592392114,0.001128092702072301
NCT00003789,Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg,0.001055316297159344,0.0009570856116850995
NCT00003897,Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma,0.00110349006176566,0.0013560355463116257
NCT00003444,"Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin",0.0009690547312006497,0.0009523455345622229
NCT00003895,Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma,0.0012655036064419412,0.0012214656806831606
NCT00003222,Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012012531586090558,0.0013519305349146337
NCT00003828,S9804: Vinorelbine in Treating Patients With Stage IV Melanoma,0.0013404776162555451,0.0013115154486441104
NCT00003665,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013812566106214097,0.0013951229957013924
NCT00003362,Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma,0.001207804410527754,0.001328055876020834
NCT00003339,Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma,0.0011966794984913307,0.0012596932878769286
NCT00062491,Study of Karenitecin (BNP1350) to Treat Malignant Melanoma,0.0012540194547958228,0.0019041020375687532
NCT00091689,Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions,0.0007878801415808071,0.0010857035250118041
NCT00057616,Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.,0.0009298681971429624,0.0010209544719286408
NCT00055562,Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma,0.000925551783949453,0.0010140180659897716
NCT00040352,"Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma",0.0008480361138390661,0.00095537853684356
NCT00034554,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,0.0013163312089733228,0.0010753456913688234
NCT00077532,Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma,0.0010558492299633413,0.0011574378016007355
NCT00053391,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012898380975264656,0.0014349734649732814
NCT00023647,Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0013812566106214097,0.0013807928730238143
NCT00039091,"Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer",0.0009552739725478658,0.0008609926367462619
NCT00039000,Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma,0.0009051131571660351,0.0010117663061890146
NCT00039234,Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver,0.0010816335565195362,0.0010573936155008601
NCT00039572,Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain,0.0010288681287826393,0.0011802914531103095
NCT00052130,Vaccine Therapy for Patients With Stage III Melanoma,0.0013654936087026785,0.0012353385017051972
NCT00052156,Vaccine Therapy for Patients With Stage IV Melanoma,0.0013812566106214097,0.0011801951100707912
NCT00059800,Boron Neutron Capture Therapy in Treating Patients With Melanoma,0.0015271465023604634,0.0013550726154225544
NCT00027742,Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma,0.001181198034247343,0.0013939208741030058
NCT00072163,Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma,0.0010275784939823864,0.0010742384270019507
NCT00072124,Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma,0.0010941711072564872,0.0011275715230031828
NCT00072345,"Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma",0.0011487151802100283,0.0013718177678298654
NCT00020358,Vaccine Therapy in Treating Patients With Melanoma,0.0015787104876690944,0.0014149360118394807
NCT00020839,Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain,0.0011063280981038145,0.0010303030964891819
NCT00068172,Study of PI-88 in Patients With Advanced Melanoma,0.0015147442051662737,0.0020724411870275115
NCT00068666,Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System,0.0010833124288098387,0.0010546242815417765
NCT00036764,BMS-247550 in Treating Patients With Stage IV Melanoma,0.0013397156589239094,0.0014240876652066292
NCT00002980,Decitabine in Treating Patients With Melanoma or Other Advanced Cancer,0.0010666820846631168,0.0013771367920374137
NCT00002455,"Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma",0.0010439933357878845,0.001095495186461998
NCT00002763,High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma,0.00111249682208862,0.0010487900842189154
NCT00002781,Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma,0.0013265961482506281,0.0013211370701490203
NCT00002973,Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma,0.001087535386496589,0.0012802571614424082
NCT00002882,Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma,0.00107522948352756,0.0009911568017114062
NCT00002535,Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma,0.0011659691782753604,0.0012242970678355406
NCT00005057,Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma,0.001164950509932803,0.0012246978447390125
NCT00005617,Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma,0.0011995787995048113,0.001390501492724754
NCT00005815,Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma,0.001178398030749537,0.00136169105916909
NCT00005633,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012898380975264656,0.0012726855526269262
NCT00005610,Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung,0.001126346477915708,0.0011461805650608379
NCT00005968,Irofulven in Treating Patients With Stage IV Melanoma,0.0013397156589239094,0.0014240876652066292
NCT00005841,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012898380975264656,0.0012745646475416943
NCT00005971,Flavopiridol in Treating Patients With Metastatic Malignant Melanoma,0.0012603906000775522,0.001356114223435937
NCT00005949,Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma,0.0011901524440405915,0.0013538503283592697
NCT00086866,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery,0.0012039262499903033,0.0012158386022793168
NCT00086489,"CP-675,206 In Patients With Advanced Melanoma",0.0016872753789608722,0.0015465828921524117
NCT00004244,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma,0.001037385509478281,0.0010167542491716151
NCT00004135,Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer,0.0010367687009620746,0.0012124572197618974
NCT00004022,Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma,0.0012003738909378246,0.0014833748667939335
NCT00004250,Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery,0.0010011199633860445,0.0009451559996644318
NCT00004104,Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma,0.0011134664602216611,0.0011148796706773492
NCT00004184,Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012570765828191883,0.0012508733202031329
NCT00004153,Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma,0.001006957149822099,0.0007967802905021855
NCT00004152,PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma,0.0011304189614337076,0.0010284534813829582
NCT00004025,Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma,0.0012012531586090558,0.0015012778995927149
NCT00004196,Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis,0.001082207937553761,0.0012076120307103794
NCT00080353,Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma,0.0008916717232065208,0.0014642504050683374
NCT00024011,PS-341 in Treating Patients With Metastatic Malignant Melanoma,0.0012611108865404003,0.0013564332590165218
NCT00001296,"A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma",0.0010393319641681979,0.0008316243087602953
NCT00001685,"Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",0.0009948191334309064,0.0011361729171966515
NCT00001439,A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant,0.0008908396338074127,0.0009759801782087723
NCT00001577,Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity,0.0008363302745765774,0.000723270411472284
NCT00035165,EPO906 Therapy in Patients With Advanced Melanoma,0.0014022455459484233,0.0012914939523794265
NCT00007969,Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012552071602277154,0.0013525628562589473
NCT00026520,Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma,0.0011730524743182502,0.001308740575524148
NCT00026221,Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.0011118494258023123,0.0009739572499121849
NCT00026143,Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma,0.0011080360436336743,0.0012353452718602963
NCT00056134,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012898380975264656,0.0014624592292460802
NCT00098553,Everolimus in Treating Patients With Stage IV Melanoma,0.0013411720061997738,0.0011295751803174353
NCT00089193,"Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.0011777774951675273,0.0011448039641483913
NCT00089219,"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma",0.0012261732509992382,0.0012680273861305727
NCT00089063,Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma,0.0011463023406249326,0.0010980320375615388
NCT00089206,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0012039262499903033,0.0012574370034035564
NCT00073892,PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma,0.00128074928186538,0.0014126593031142448
NCT00032045,Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.001200853159805665,0.0012573965693956095
NCT00090896,"CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery",0.001146677967440337,0.0012817252944727071
NCT00031733,Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma,0.0010149729050150844,0.001091994064529907
NCT00095108,Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer,0.0009431049791027115,0.000977171670786807
NCT00070642,CPG 7909 Injection in Melanoma,0.0014592843099860643,0.0012592265863179718
NCT00070343,Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301,0.001110114425533474,0.0011517504098396208
NCT01456104,Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma,0.0009998988483799953,0.0011130308626284596
NCT01496807,Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma,0.0008682298192048978,0.0010046561808724373
NCT01460875,Recombinant Interferon Alfa-2b in Treating Patients With Melanoma,0.0015349753409378696,0.001507505128393999
NCT01425749,Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI,0.0008990039350784065,0.0010578096966715911
NCT01409733,TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients,0.0009865758814099268,0.0011039476272619786
NCT01489423,Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim,0.001156719047024193,0.0012052378163938762
NCT01489059,Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma,0.00111224509428772,0.0010508503720555867
NCT01433991,E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),0.000989363492005323,0.0011219485622734628
NCT01482260,Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma,0.0014491462581061002,0.0010950616966098241
NCT01480154,"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",0.001061391043976745,0.0012148282489032516
NCT01444560,"miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi",0.0007469182263095744,0.0006566389900277225
NCT01495572,Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells,0.000839301297564999,0.0010734247477225786
NCT01495988,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,0.0011098344835825805,0.0011160621921057347
NCT01432860,A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination,0.0009970783961554715,0.0006406624027037043
NCT01462773,"Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma",0.0011637661116094536,0.0010772185137280282
NCT01453361,Phase II FANG™ in Advanced Melanoma,0.0011844343388563376,0.0009629244548274582
NCT01469455,DNA Repair Inhibitor & Irradiation on Melanoma,0.000852675849257123,0.0011027763694646704
NCT01449279,Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,0.0010194954673606118,0.0009026840558245977
NCT01435499,Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma,0.001130885194725438,0.0012522624096936769
NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,0.0013536213308142117,0.0011247087001030093
NCT01455259,Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors,0.0009383186322705578,0.0009847268879410985
NCT01455103,Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma,0.0011448572693527493,0.001424871904775438
NCT01295931,Nuclear and Near-Infrared (NIR) Imaging in Melanoma,0.001465535395443639,0.0006582748593845153
NCT01295827,"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)",0.0009311021931065229,0.0011399563258640266
NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,0.0014081453640923183,0.0013088622477728626
NCT01253096,Intratumoral Application of L19IL2 in Patients With Malignant Melanoma,0.0015262996950358605,0.0015004211699930314
NCT01213732,Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma,0.0009183063438896439,0.000889763440039005
NCT01266096,PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study,0.0010973780887442671,0.001058709623224743
NCT01259934,Nordic Adjuvant IFN Melanoma Trial,0.002777704469023434,0.00106586210252221
NCT01288963,"IL-2 ""SELECT"" Tissue Collection Protocol in Patients With Advanced Melanoma",0.0010913870488965557,0.001217860822154971
NCT01227551,A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma,0.0013414461691437138,0.0012585128325953434
NCT01227889,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,0.0010938749210278,0.0010341611041809102
NCT01216696,Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1,0.0011432203291881619,0.0011231828182664844
NCT01216787,"RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery",0.0011674484868655966,0.0012898386932013188
NCT01256359,Docetaxel With or Without AZD6244 in Melanoma,0.0014536248192060723,0.0012392832324633432
NCT01245062,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,0.0008994125139250799,0.0009977133587918197
NCT01245556,Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma,0.0010772409272309718,0.0013677008284610854
NCT01280565,A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit,0.001332456055212043,0.0010497492188755162
NCT01281722,Role of SLURP-1 in Melanoma and Melanoma Stem Cells,0.0008531401325465316,0.0008188626862986
NCT01239134,Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,0.0009845487500925345,0.0010496879621513596
NCT01211262,Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma,0.0008880577394819822,0.0009990041537786037
NCT01205815,Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment,0.001288279711264603,0.0010987172273953527
NCT01247623,Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma,0.0011301606577816907,0.0013341692368101967
NCT01274338,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,0.001124868733719886,0.0013146331575955071
NCT01209676,IMCgp100 in Advanced Unresectable Melanoma,0.0010036697603779633,0.0007846514051852733
NCT01264731,Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma,0.0007183612294272023,0.0008617744646342245
NCT01264081,Lapatinib in Stage IV Melanoma With ERBB4 Mutations,0.0011909212053981808,0.001195761522181759
NCT01278940,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma,0.0012175291793690072,0.0009822312602475486
NCT01258855,Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0010879967485385672,0.0012713501255018477
NCT02941744,A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases,0.0007414279609953307,0.0008341630248347617
NCT02990416,A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,0.0008427890416354895,0.000949294211837867
NCT02990611,Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma,0.0011771305566384838,0.0011395803905260922
NCT02917473,Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma,0.0009411583972689686,0.0008827813465334194
NCT02907827,Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.,0.0009935151913433864,0.0006759773408559497
NCT02907086,Circulating Tumor Material in Colorectal Cancer and Melanoma,0.0010695279191272355,0.0010489129460763084
NCT02975700,A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma,0.001288609191687146,0.0013325055576979702
NCT02938728,Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma,0.0008243413619569469,0.0012734439198558716
NCT02981303,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,0.0009458476879039166,0.001104117394677076
NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,0.0010363197735759238,0.0009925669492203421
NCT02970981,Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,0.001214651251163721,0.0013553785116028328
NCT02909348,Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab,0.0011347873939245594,0.0010350713329541792
NCT02939300,Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,0.0009149179529810021,0.0010650796886354406
NCT02994498,DCB-BO1301 for Advanced Melanoma,0.0016929682068813478,0.0012901544788759634
NCT02978625,Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,0.0011035736805314732,0.0012551174873332014
NCT02905266,A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma,0.00089707453386246,0.001014374163518702
NCT02989064,"MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers",0.0010421751873831635,0.0009012372869809371
NCT02965716,Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,0.0013494437161882334,0.0013484032097980817
NCT02962947,MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients,0.0012204330631640013,0.0011586275795735447
NCT02974803,Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,0.0010094910728384243,0.0009535227133426287
NCT02993315,Melanoma Patients Immunized With Natural DenDritic Cells,0.0015526887861715309,0.0011192158778215585
NCT02915666,A Clinical Trial of Patients With Melanoma,0.0015340150073470031,0.0011173657980811335
NCT02983006,Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,0.0010164508129813176,0.001111036241310625
NCT02910557,Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection,0.0012082189775871324,0.001099463749145916
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",0.0009533065548264777,0.0009835459898731248
NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,0.00097784289725248,0.0009358325259698938
NCT02507947,SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access,0.0010942341499211178,0.0010063564403177336
NCT02507076,Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma,0.0010206454386756526,0.0011398702593284113
NCT02519322,Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,0.001131463771448268,0.001160537120826499
NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Hodgkin Lymphoma or Other Solid Tumors",0.0008198406790119306,0.0007910947665575293
NCT02508909,Videoscopic Ilioinguinal Lymphadenectomy for Melanoma,0.0014506189293849111,0.0006726198849822156
NCT02545075,A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine,0.000853653756275923,0.0010212304192088783
NCT02553642,Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),0.0010967538464619548,0.0010736741216647986
NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,0.0008098435113459456,0.00113685193700106
NCT02511119,Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma,0.000696853425247771,0.0007490851511742536
NCT02574377,myDC/pDC in Stage III Melanoma Patients,0.0016727462566609114,0.0012034292513998426
NCT02574533,Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma,0.0010125913442231465,0.0012536841021653024
NCT02509598,"A Study Comparing Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping",0.0010944508481502229,0.0009373589871999554
NCT02565992,Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma,0.0011560774855946879,0.001014027102771911
NCT02599402,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,0.001145603988418555,0.0013287875211664536
NCT02506153,"High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",0.0011275686788602898,0.0011208315493833644
NCT02581228,"Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy",0.0011441083055790883,0.0011049759284864336
NCT02562625,Trial of Pembrolizumab and Radiotherapy in Melanoma,0.0010785229411146087,0.001092299782270548
NCT02575404,GR-MD-02 Plus Pembrolizumab in Melanoma Patients,0.0015576092866015443,0.0019076887945290075
NCT02501551,"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",0.0008973353531635346,0.000815140789629685
NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,0.0008680459020376191,0.0008196901019685101
NCT02587650,Trial of TKF Inhibition in Unresectable Stage III/IV BRAF/NRAS WT Melanoma,0.0009926289321846216,0.0010802062288726856
NCT00685750,Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma,0.0007247398811463303,0.00104036116394775
NCT00626405,Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery,0.0010956546127876788,0.0011252719388582385
NCT00626860,The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma,0.0011279338872468997,0.0013966715747139565
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,0.0016872753789608722,0.001253341837433527
NCT00667901,Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery,0.0011726180388929159,0.0013087843497081749
NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",0.000967037042677423,0.0006706741876034365
NCT00667953,Study of Temzolomide and Gleevec in Advanced Melanoma,0.0011306015423038318,0.001177183742283012
NCT00623766,Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases,0.0008193658009906513,0.0014466073941620955
NCT00636168,Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma,0.0009135698613182459,0.0008391347326232111
NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",0.000954748714604975,0.0009549389444929551
NCT00610311,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma,0.0008784807275135109,0.0011834791434730306
NCT00610857,Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma,0.001107969672632554,0.0009618100526999561
NCT00625768,Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma,0.0011601062376857115,0.0011753202080042413
NCT00683670,Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma,0.000873152981443003,0.0010867712370907009
NCT00665470,Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma,0.0007606048306126702,0.0012948532814306395
NCT00672542,Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells,0.0008069811605179233,0.0010354295537792157
NCT00672321,"Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma",0.0009952293657387494,0.0007257494420971569
NCT00669019,Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011717237648243976,0.0012101297825794857
NCT00658892,Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma,0.0013426054112444545,0.0009157039738185075
NCT00658437,CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy,0.0010226607324252696,0.0012330892755483003
NCT00651703,Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients,0.0010888384711512133,0.0011982070981749712
NCT00612222,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma,0.0009939957539743674,0.00118786951625107
NCT00612664,"Phase II, 2nd Line Melanoma - RAND Monotherapy",0.0014551920819305382,0.0011468101945897517
NCT00675727,Safety Study of CADI-05 in Patients With Advanced Stage Melanoma,0.0013417718460997559,0.0012495936869760613
NCT00688090,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.,0.0010155882688154992,0.0010669411701797228
NCT00601861,Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer,0.0007571412353350489,0.0007357517884961811
NCT00661336,A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma,0.001056948841511512,0.0010435298140199026
NCT00602576,Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma,0.0010777594624882248,0.0010570952533592401
NCT00615095,Differential Risks for Melanoma: p16 and DNA Repair,0.0014506528774767117,0.0007819431915348058
NCT00615160,PTK/ZK in Disseminated Malignant Melanoma,0.001450693722745973,0.0009455037214076147
NCT00698100,"Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines",0.0010993898211564754,0.0010174491621203429
NCT00671554,Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma,0.001028313937268623,0.0010890165301208306
NCT00671918,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,0.000704666935298876,0.0006291982831314205
NCT00398073,"Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma",0.001217411230587593,0.0011961102175145353
NCT00349206,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.0010634799689310391,0.0010572094427446404
NCT00306553,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.001112280800368296,0.0012280420970564503
NCT00306566,Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients,0.0010921049957352447,0.0011293959773126018
NCT00306514,Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients,0.001112280800368296,0.0012097315898125871
NCT00358319,Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma,0.001022425829792442,0.001046540681891098
NCT00383292,A Study of LY573636 in Treating Patients With Malignant Melanoma,0.001755885322770282,0.0013180033434836392
NCT00383851,Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma,0.0009758146447826926,0.0011406968014290918
NCT00328861,Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer,0.0008584392968126742,0.0013898988880542444
NCT00346008,Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members,0.0015261906849186413,0.0008544172828202019
NCT00368615,Characterization of the Melanoma-Specific Immune Response,0.0008525956057258961,0.0010241914751895906
NCT00370136,Sentinel Node With Ultrasound Contrast in Melanoma,0.0008310467036407313,0.0005374269792572794
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,0.0014551206522656196,0.0008805410787366355
NCT00348088,Melanoma Biomarker Study,0.001271736012242769,0.0009254290428558503
NCT00304200,Temodar and Sutent as Therapy for Melanoma,0.0008951160247837145,0.0009800529734690507
NCT00397982,Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma,0.001167886111418585,0.001033541199426766
NCT00394134,Targeted Intervention for Melanoma Prevention,0.0010244335151624448,0.0007030845619424592
NCT00365937,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,0.0010737927390736457,0.0008956882764064031
NCT00356460,Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma,0.0012560158978572986,0.0009183451670174951
NCT00313235,Combined Modality Treatment for Patients With Stage IV Melanoma,0.001341981395559125,0.0012738279021439391
NCT00387751,Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,0.0011604931183225014,0.0010568139531487153
NCT00391300,Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions,0.0009605240326141445,0.0007467571027874316
NCT00341991,Molecular Epidemiology of Cutaneous Malignant Melanoma,0.0010248935585762304,0.0007449174919403603
NCT00357461,Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma,0.0012507600137373683,0.0012188197211792367
NCT00395070,A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma,0.0011748836045864764,0.0011514474399412535
NCT00300612,Vaccine Treatment for Advanced Malignant Melanoma,0.0010375597907212606,0.0014088427516756978
NCT00390338,Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma,0.0012898380975264656,0.0012379529865871564
NCT00317759,Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma,0.0011651184659548614,0.0013253478680256788
NCT00327600,Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma,0.0009709174800171403,0.00106827387813135
NCT00339222,Family Study of Melanoma in Italy,0.0014491462581061002,0.0007370474081623207
NCT00324155,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,0.0008440436681153037,0.000981291951451807
NCT00324727,Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma,0.0010227481142789706,0.0010776046618467885
NCT00323206,Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma,0.0010292963106361959,0.0010383161180143074
NCT00791271,Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion,0.0008400930567910673,0.0009039153716202052
NCT00723710,Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600),0.0011153654354874646,0.0009996815971674608
NCT00794235,Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine,0.0008518755092589717,0.0009596782232017279
NCT00790010,Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma,0.001154205367582515,0.001131904441744894
NCT00746746,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,0.0009285172613512238,0.0009732516953638085
NCT00749684,Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083),0.0009007135521226305,0.000839448125239933
NCT00716495,"Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma",0.0009933960332054483,0.0010277701345214442
NCT00726739,Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma,0.0012042501355946286,0.001183431222473423
NCT00733798,A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma,0.001393181359893279,0.0015910526387742157
NCT00700882,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",0.0011081311520957002,0.0010434716419966722
NCT00769704,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,0.0010121204396575261,0.001116062327589292
NCT00796445,"A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor",0.0011402814988369983,0.001128782258461837
NCT00707161,Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma,0.0008479494867006455,0.0011203359871895715
NCT00788775,"Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma",0.0009881087385026233,0.0009435223993283191
NCT00755976,Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma,0.001098346686044261,0.001058097888094872
NCT00706992,Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients,0.0012415891419439037,0.0014181529851982658
NCT00722098,Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients,0.0011795715553504088,0.001186378332505487
NCT00776945,Feasibility and Functionality of fPAM Imaging in Melanoma,0.0010338403225543494,0.0006545575273221014
NCT00743496,"A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma",0.0007402517138990301,0.0009470846935891158
NCT00705640,Vaccine Therapy in Treating Patients With Advanced Melanoma,0.0013781770152279035,0.0012679968138687668
NCT00729950,Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,0.0011229631982353108,0.0011892535013552667
NCT00445783,Study of Families With Melanoma,0.0017944866535682719,0.0011070783289912798
NCT00466687,Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma,0.0011713136175530992,0.0009810284760974968
NCT00477906,M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma,0.0010480077815819844,0.0013558194646852344
NCT00450255,VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.001171723764824398,0.0010920570604009445
NCT00450593,Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma,0.0012128752439638725,0.0011066352405797264
NCT00457418,High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2),0.0011405999030910362,0.0011472370277635965
NCT00492505,"Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",0.0010481148232250402,0.0010462787433368126
NCT00412828,A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma,0.0010401626931369258,0.0009974786078181508
NCT00409383,Abraxane and Temodar Plus Genasense in Advanced Melanoma,0.0008439078255343922,0.0009949060624796844
NCT00429312,A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma,0.0010061130733471217,0.0013983447964816724
NCT00472459,PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer,0.0007396997864632829,0.0009511742342754088
NCT00463892,High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes,0.0007129427886265216,0.0009434575054123611
NCT00424515,Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma,0.0012150570753340644,0.0009299093259667956
NCT00436605,Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma,0.001172556826114719,0.001152567469834906
NCT00462280,Lovastatin in Treating Patients At High Risk of Melanoma,0.0012180482860776052,0.001403255821813604
NCT00462423,"Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study",0.001174437376693247,0.0010711025178161678
NCT00462982,Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma,0.001081969403387478,0.0011407933983300777
NCT00447356,High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma,0.0010866734877862994,0.0009534766157807873
NCT00406900,Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma,0.0007896360372302001,0.0009444624548412788
NCT00432107,A Study to Assess APO866 for the Treatment of Advanced Melanoma,0.0011961959088296536,0.0011108557755902771
NCT00432471,Optical Imaging of Skin Cancers for Margin Delineation of Non-melanoma Skin Cancers,0.0010305447923445515,0.0007996508826840282
NCT00416988,Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants,0.0007431250487551121,0.0005740200171450103
NCT00404235,Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,0.0011464836098622091,0.0011164124675849178
NCT00470015,"Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",0.001142396262390648,0.0011661808838476257
NCT00470379,"Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery",0.0011749449857902977,0.0011746967152101682
NCT00470470,Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0011721396655572877,0.0012104206589071322
NCT00438984,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma",0.001089964346494486,0.001179807957675597
NCT00438009,A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients,0.001390952481963604,0.0009848943861583371
NCT00471133,Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation,0.0008366151830253391,0.0008580498346424683
NCT00471887,"Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma",0.0011915402816495438,0.0010398718785226645
NCT00471471,Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery,0.0012039262499903033,0.0011490897628054244
NCT00498979,"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",0.0008189232005331611,0.0009049514438395422
NCT00498836,"Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",0.0010266317158010877,0.000785045980606419
NCT00453050,Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin,0.0010993387948009426,0.0011118984080226342
NCT00482105,Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells,0.0006972988089366253,0.0006348941229055911
NCT00495066,Compassionate Use Trial for Unresectable Melanoma With Ipilimumab,0.0009423195245683221,0.000992398999027747
NCT01886235,Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery,0.0010383920467728484,0.001218652023383072
NCT01840527,Utility of Novel BRAF Test for Melanoma,0.0014564324876534134,0.0009168033037871902
NCT01840007,Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma,0.0012559887805096215,0.0009679276693539812
NCT01888081,A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma,0.0008517629401861536,0.0010378131202399726
NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,0.0010326552137345016,0.001036138228662384
NCT01864538,A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma,0.0011448572693527493,0.001179426402348439
NCT01826448,"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",0.0009430716470571264,0.0009491280684086136
NCT01826864,Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma,0.0010202155629153167,0.0013107325943023872
NCT01883323,Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma,0.0010193920267964384,0.0011550342420222923
NCT01894672,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",0.0011538227142385959,0.001359513322999973
NCT01897116,A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,0.0011849916413470272,0.0015883488645451233
NCT01867619,"Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",0.001081030377155767,0.001102665308868893
NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,0.0010852622235816632,0.001201607445409344
NCT01878396,Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors,0.0011167524716288464,0.0013722720225850182
NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,0.0009967467885733854,0.0013955655863844482
NCT01859845,Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma,0.0006797290177610054,0.000689613275396553
NCT01866319,Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006),0.0009727292559466199,0.0009954820769274742
NCT01844505,Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067),0.0009658271674347571,0.0010930378576760509
NCT01898403,Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma,0.0010638837794460015,0.0010637179335700098
NCT01841463,Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,0.0013182955521558683,0.0010237253715862135
NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,0.0010554896358530713,0.001208220482265504
NCT01851408,"Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",0.0010634799689310391,0.0010572094427446404
NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,0.0011323946618445016,0.0011744017880147145
NCT01920516,Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment,0.0008034306266454221,0.0010719112284276015
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,0.0010703253434054692,0.0011452979644948527
NCT01989585,"Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",0.0010610083744931633,0.0011485532913335624
NCT01989572,Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma,0.0010891672962774625,0.0012454582502693361
NCT01989559,Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery,0.0010006407651421516,0.0011452732177909374
NCT01996202,A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma,0.0009002895846933817,0.0009062279386862753
NCT01990859,Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients,0.0013663586088378853,0.0021240836716761285
NCT01959633,Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation,0.0012105851946469424,0.0012794911078883417
NCT01946373,T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma,0.0010898770105172099,0.0010683575461788311
NCT01943422,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,0.0009281590403767403,0.0013365861249767825
NCT01944709,Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma,0.0012748539539433861,0.001233941152877348
NCT01986712,A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma,0.0011237972575715272,0.0011047803222138958
NCT01940809,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",0.0010940015555028638,0.0012509669784438555
NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,0.0007592664198933797,0.001064948837321902
NCT01973608,MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma,0.0011844343388563376,0.0007498929451399986
NCT01961115,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,0.00118437990727618,0.0014292432576415322
NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma,0.0014860224687529365,0.0010997346309515297
NCT01983124,Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib,0.0011838524546789705,0.0013510718037516181
NCT01970358,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,0.0012599081838152596,0.001014871891763132
NCT01970527,Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,0.0012161391179931647,0.0011443128884721613
NCT01904123,A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma,0.001230043482968612,0.001104502792717271
NCT01942993,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,0.000924955781833943,0.0011765852324113204
NCT01988831,Efficacy of Propranolol Treatment to Prevent Melanoma Progression,0.0007923673558769121,0.00094180262302037
NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",0.0007356612751638727,0.0008547545011659686
NCT01984255,"A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients",0.0010780558146260603,0.0009680698573265346
NCT02694965,Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma,0.0008584875779631397,0.000903990597110599
NCT02602756,Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas,0.0010084286236967254,0.0008390107015560885
NCT02605473,Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion,0.0008400930567910673,0.000947240262289468
NCT02659540,A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,0.0009339172126329653,0.0009445854399464579
NCT02696356,Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma,0.0012696598548393313,0.0011802586285802564
NCT02612168,Melanoma Image Analysis Algorithm (MIAA) Validation Study,0.00100782926004589,0.0007789846055213711
NCT02671513,A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients,0.0013175427134373614,0.0017542228890375107
NCT02613325,fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth,0.0008328432656718039,0.0009178742720163196
NCT02625337,Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients,0.0011438332881386574,0.0009903949773611479
NCT02650492,Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma,0.0007392023918207855,0.0009742146470658452
NCT02600169,Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab,0.0010230540321824182,0.001116180684957334
NCT02600143,Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.,0.0010032979309537156,0.0008348693312565018
NCT02668887,Employment and Quality of Life in Patients With Malignant Melanoma,0.0015271618699940848,0.0010465846980602695
NCT02656706,BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,0.0009080568959669388,0.0008398884107266888
NCT02673970,Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma,0.0011052426893543184,0.0011599863208909822
NCT02662725,Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases,0.0011284984813955412,0.0009095230438706713
